Hemispherx Biopharma Inc (HEB) Key Developments | Reuters.com
Edition:
United States

Hemispherx Biopharma Inc (HEB)

HEB on American Stock Exchange

0.12USD
24 Jun 2016
Change (% chg)

$-0.00 (-3.75%)
Prev Close
$0.12
Open
$0.11
Day's High
$0.12
Day's Low
$0.10
Volume
746,516
Avg. Vol
667,023
52-wk High
$0.23
52-wk Low
$0.06

Latest Key Developments (Source: Significant Developments)

Hemispherx Biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation
Wednesday, 8 Jun 2016 11:53am EDT 

Hemispherx Biopharma : Hemispherx biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation, resolving disputes with insurance carriers, and obtaining commitments of $3.5 million in payments to company . Two pending disputes in mediation with company insurers have also been settled with a commitment to pay $3,500,000 to company .All four derivative cases have now been settled, subject to final court approval.  Full Article

Hemispherx Biopharma amends and restates agreement with myTomorrows
Monday, 23 May 2016 08:30am EDT 

Hemispherx Biopharma Inc : Hemispherx amends and restates agreement with myTomorrows for the early access program for rintatolimod in Europe . Executed an amended and restated agreement with Impatients, N.V., a Netherlands based company doing business as myTomorrows .MyTomorrows will perform EAP activities in Europe, Turkey to include supply of rintatolimod for treatment of chronic fatigue syndrome.  Full Article

Hemispherx Biopharma qtrly loss per share $0.01
Monday, 16 May 2016 05:09pm EDT 

Hemispherx Biopharma Inc : Hemispherx biopharma announces financial results for the three months ended march 31, 2016 .Quarterly loss per share $0.01.  Full Article

Hemispherx Biopharma Inc receives European patent office grant of new composition of matter patent covering ampligen formulations
Monday, 28 Sep 2015 08:30am EDT 

Hemispherx Biopharma Inc:Says that it received formal notice on Sept. 21, that European Patent Office's Examining Division granted the company's application titled " Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity ".  Full Article

Hemispherx Biopharma appoints new president
Thursday, 13 Aug 2015 08:30am EDT 

Hemispherx Biopharma, Inc:Announced that the Board has appointed Thomas Equels as the new President.  Full Article

Hemispherx Biopharma Inc expands its collaboration With Emerge Health
Tuesday, 11 Aug 2015 08:30am EDT 

Hemispherx Biopharma Inc:Has executed an agreement with Emerge Health Pty Ltd. (Emerge).To seek approval of Alferon N Injection in Australia and New Zealand and to commence distribution of Alferon in both countries on a named-patient basis, where deemed appropriate.Will collaborate on seeking regulatory approval from Australia's Therapeutic Goods Administration (TGA) and New Zealand's Medicines and Medical Devices Safety Authority.Under an exclusive license to sell, market, and distribute Alferon N Injection in Australia and New Zealand, Emerge will implement regulatory-compliant programs to educate physicians about Alferon.Hemispherx will support these efforts and will supply Alferon at predetermined transfer price.  Full Article

Hemispherx Biopharma Inc Europe N.V./S.A. submits application for orphan medicine designation to EMA for Alferon N Injection for treatment of middle east respiratory syndrome (MERS)
Wednesday, 15 Jul 2015 08:30am EDT 

Hemispherx Biopharma Inc:Have submitted an application for orphan drug designation to European Medicines Agency (EMA) for Alferon N Injection, an experimental therapeutic, to treat Middle East Respiratory Syndrome (MERS).Says EMA has determined application to be valid, and the Committee for Orphan Medicinal Products (COMP) has initiated official review process.It is anticipated that the COMP will give an opinion on the application within the next 90 days.There are significant benefits for achieving Orphan Designation, including eligibility for grants from EU and Member State programs.Designated orphan medicines are assessed for marketing authorization centrally in European Union with reductions/waivers in fees and costs of overall regulatory process.Says designation allows companies to make a single application to the European Medicines Agency, resulting in single opinion and a single decision from the European Commission, valid in all EU Member States.Authorized orphan medications, once commercially approved, receive benefits including ten years of complete protection from market competition with similar medicines.  Full Article

Hemispherx Biopharma Inc Europe N.V./S.A. receives orphan medicine designation by European Medicines Agency for Ampligen to treat patients with ebola virus disease
Monday, 11 May 2015 08:30am EDT 

Hemispherx Biopharma Inc:Says that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A., received formal notification from European Commission [EU/3/15/1480-EMA/OD/310/14].Approving its Orphan Medicinal Product Application for Ampligen, an experimental therapeutic, to treat Ebola Virus Disease (EVD).  Full Article

Hemispherx Biopharma Inc's Europe N.V./S.A. receives positive opinion on application for orphan designation by European Medicines Agency for Ampligen to treat patients with ebola virus disease
Tuesday, 24 Mar 2015 08:30am EDT 

Hemispherx Biopharma Inc:Says that European subsidiary, Hemispherx Biopharma Europe N.V./S.A gained positive opinion from COMP (Committee on Medical Products).Regarding its Orphan Medicinal Product Application for Ampligen, an experimental therapeutic, to treat Ebola Virus Disease (EVD).Hemispherx submitted in vitro and in vivo data in appropriate preclinical models relevant to the EVD indication to the European Union Committee for Orphan Medicinal Products.In addition to efficacy data, clinical safety information was also included in comprehensive application.  Full Article

Hemispherx enters collaboration with Emerge Health for commercialization of Ampligen for Chronic Fatigue Syndrome (CFS) in Australia and New Zealand
Monday, 9 Mar 2015 08:30am EDT 

Hemispherx Biopharma Inc:Executes an agreement with Emerge Health Pty Ltd. to seek approval of Ampligen, an experimental immunotherapeutic, for Chronic Fatigue Syndrome in Australia and New Zealand and to commence distribution of Ampligen in both countries on a named-patient basis, where deemed appropriate.Hemispherx and Emerge will collaborate on seeking regulatory approval from Australia's Therapeutic Goods Administration and New Zealand's Medicines and Medical Devices Safety Authority.  Full Article

BRIEF-Hemispherx Biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation

* Hemispherx biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation, resolving disputes with insurance carriers, and obtaining commitments of $3.5 million in payments to company